SCCS Final Opinion on HAA299 (Nano)
HAA299 (non-nano) has been used in cosmetic products as a UV filter. In 2014, the SCCS considered that this ingredient in its non-nano form was safe for use as a UV-filter in cosmetics, at a maximum concentration of 10%. The SCCS released its final opinion regarding the use of HAA299 in its nano form.
Picture of Marta Pinto

Marta Pinto

Regulatory Affairs Associate


HAA299 (CAS number: 919803-06-8), also called Bis-(Diethylaminohydroxybenzoyl Benzoyl) Piperazine (INCI name) is an organic compound used as a UV-filter in cosmetics and personal care products. HAA299 (nano form and non-nano) is not currently included in the Annexes of the European Cosmetics Regulation (Regulation (EC) No 1223/2009).

In 2014, the European Commission’s Scientific Committee on Consumer Safety (SCCS) issued an opinion regarding the use of HAA299 as UV filter in sunscreen products. The SCCS concluded that the use of non-nano HAA299 (micronized or non-micronized, with median particle size distribution around 134 nm or larger) at a concentration up to 10% as an UV-filter in cosmetic products, does not pose a risk of systemic toxicity in humans. The SCCS safety evaluation does not apply to inhalation exposure and covered only the HAA299 in the non-nano form, not covering when this ingredient is composed of nano particles.

HAA299 has low oral bioavailability and scientific evidence shows an overall very low or lack of dermal absorption of HAA299 in human skin. Non-micronized HAA299 was not a dermal irritant when applied in rabbits but it caused slight irritation in the eyes of rabbits. No delayed contact hypersensitivity was observed in a murine Local Lymph Node Assay (LLNA), but the sensitization potential of HAA299 could not be ruled out by the SCCS. Phototoxicity studies with HAA299 indicate that this ingredient has no phototoxic, photoallergic or photogenotoxic potential.


The SCCS released its new opinion regarding the safety of HAA299 in its nano-form (aqueous dispersion of nanoparticles formulation with excipients containing the HAA299 active UV filter ingredient that was micronized to nano size).

The available data indicated that HAA299 in the nano-form is a practically insoluble material, with very low dermal and oral absorption. Nano HAA299 did not show skin irritation potential or caused ocular corrosion or severe ocular irritation in in vitro tests. Skin sensitizing and phototoxic potential are considered unlikely.

The SCCS expressed concerns regarding the repeated use of products containing nano HAA299, due to the inflammatory effects on the lung after acute inhalation exposure. The Committee does not recommend the use of this ingredient in applications that could lead to exposure of the consumer’s lungs via inhalation.

Considering the currently available scientific evidence, which shows an overall very low or lack of dermal absorption of nano HAA299, the SCCS considers that “HAA299, either as non-nano or nano form, is safe when used as a UV-filter in dermally-applied cosmetic products up to a maximum concentration of 10%”. Moreover, the Committee indicated that the combined maximum concentration of the two forms (nano and non-nano) should not exceed 10% in cosmetic products.

The SCCS may consider the revision of its opinion if new evidence emerges in the future to show that nano HAA299 used as UV-filter in cosmetic products can penetrate human skin to reach viable cells in higher levels than demonstrated in the submission.

If you wish to get more information on the safety of cosmetic ingredients, feel free to contact us at


  1. Regulation (EC) No 1223/2009 of the European Parliament and of the Council of 30 November 2009 on cosmetic products.
  2. Scientific Committee on Consumer Safety (SCCS). Opinion on HAA299 (nano). SCCS/1634/21. 2021
  3. Scientific Committee on Consumer Safety (SCCS). Opinion on 2-(4-(2-(4-Diethylamino-2-hydroxy-benzoyl)-benzoyl)- piperazine-1-carbonyl)-phenyl)- (4-diethylamino-2- hydroxyphenyl)-methanone (HAA299) as UV filter in sunscreen products. SCCS/1533/14. 2014


medical devices

Safety Reporting in Clinical Investigations: a Gap Analysis of Guidance Documents 

Safety reporting in clinical investigations of medical devices shall be performed in line with Article 80(2) of the EU MDR. On May 2020, it was published the MDCG 2020-10/1, outlining the procedures for safety reporting in clinical investigations of medical devices under the EU MDR. However, on October 2022 the Medical Device Coordination Group (MDCG) published an updated version of the MDCG 2020-10/1, the MDCG 2020-10/1 Rev 1. This article highlights the updates included in the new revision, analysing the gaps between both documents.

Read More »
medical devices

Roles and Responsibilities of an Authorised Representative under EU MDR and IVDR 

If a medical device manufacturer is not established in a Member State, the devices can only be placed on the Union market if the manufacturer designates an authorised representative. The authorised representative plays a pivotal role in ensuring the compliance of the devices with EU regulation, serving as point of contact. The obligations and responsibilities of authorised representative are outlined on Article 11 of both MDR and IVDR, but clarification of relevant requirements is described in MDCG 2022-16 of October 2022.

Read More »
medical devices

Understanding the ISO Standards Lifecycle

ISO Standards cover a huge range of activities, representing the distilled wisdom of people with expertise in their subject matter and providing the regulators with a sound basis to develop better legislation. ISO Standards are diverse, addressing from the shoe size we wear to the quality of air we breathe. The medical device sector is no exception. ISO has many International Standards and guidance documents aimed at helping the sector ensure safe and effective medical devices while meeting the multitude of national, regional and international regulatory requirements. But how exactly is a Standard developed, reviewed and withdraw?

Read More »
medical devices

Amendments to the Transitional Provisions of the European Union MDR and IVDR

The proposed amendments aim to maintain patients’ access to a wide range of medical devices while ensuring the transition to the new framework. The ammendments proposal aims to extend the current transition period (Article 120 of the MDR), and it also deletes the ‘sell-off’ deadlines of both MDR and IVDR. The extension is staggered depending on the risk class of the device – until December 2027 for high-risk devices and December 2028 for medium and lower-risk devices.

Read More »
medical devices

EU MDR – Proposal for Extension of Transition Period

The transition to MDR has been slower than anticipated by the European Commission. Insufficient capacity of notified bodies and the low level of preparedness of manufacturers led to a proposal for extension of current MDR transition period with deadlines depending on the risk class of the devices.

Read More »
medical devices

MDCG 2022-18 – EU MDR Article 97

EU MDR Article 97 may be a temporary solution to avoid disruption of supply of Medical Devices on the EU Market. The MDCG 2022-18 presents a uniform approach for application of MDR Article 97 on non-compliant legacy devices under the conditions set by the competent authorities, while limiting the impact on the supply of safe and effective devices.

Read More »
cosmetic products

EU to set Labelling Requirements for 56 additional Fragrance Allergens in Cosmetic Products

World Trade Organization (WTO) has been notified by the European Commission of a draft amendment to Regulation (EC) No 1223/2009 as regards labelling of fragrance allergens in Cosmetic Products. The proposed date of adoption of the new regulation is expected to be in the first half of 2023 and the propose date of entry in force 20 days from the publication in the Official Journal of the European Union.

Read More »
cosmetic products

New Amendments to the European Cosmetics Regulation – CMR Substances

The European Commission published the Commission Regulation (EU) 2022/1531, which amends Regulation (EC) No 1223/2009 in regards to the use in cosmetic products of certain substances classified as CMR. This amendment introduces new entries to Annex II and Annex III and revises an entry to Annex V to Regulation (EC) No 1223/2009.

Read More »